

# CPNP Announcements

## MEET YOUR NEWLY ELECTED BOARD MEMBERS

The College of Psychiatric and Neurologic Pharmacists (CPNP) membership has elected three officers to serve on the 2014-2016 Board of Directors. Assuming their offices effective July 1, 2014, will be President-Elect Drs. Raymond Love, Secretary Jennifer Zacher, and Member at Large Jonathan Lacro. Dr. Love is currently serving the first year of a two-year term as Member at Large to the Board. With his selection as President-Elect, a vacancy on the board will occur on July 1, 2014. CPNP bylaws require that President-Elect Steve Burghart name an individual to complete this 1-year term. Dr. Megan Ehret has been selected and endorsed by the CPNP Board as the individual to complete this term.



**Ray Love, PharmD, BCPP, FASHP**, is currently serving his first term as Member at Large on the Board of Directors. Ray has a long history with CPNP and the promotion of psychiatric pharmacy practice. He was the 2010 recipient of the Saklad Memorial Award. Since beginning practice in 1977, Ray established the first ASHP accredited residency clinical residency at the University of Maryland School of Pharmacy, one of the first statewide clozapine monitoring programs, a statewide program to address antipsychotic use in children and the University's Mental Health Pharmacy Program which furnishes services to five state psychiatric hospitals and Maryland Medicaid. He served as a member of the Maryland Board of Pharmacy where he helped establish pharmacist delivered collaborative drug therapy management in Maryland. He currently directs the Mental Health Pharmacy Program which includes 30 pharmacists in psychiatric practice throughout Maryland. In addition, he also directs the Maryland Peer Review for Mental Health Drugs in Children and Adolescents Program, a cooperative program between Maryland Medicaid, the University of Maryland School of Pharmacy and Department of Psychiatry and the Maryland Psychiatric Research Center.



**Jennifer L. Zacher, PharmD, BCPP**, joined CPNP as a student in 2004. Since then, she has since been actively involved in the organization in a variety of capacities and has served CPNP through leadership and collaboration. Most recently Dr. Zacher has served as Program and Annual Meeting Chair and as a member of the Psychiatric Pharmacotherapy Review Course Editorial Board. Jennifer

works as an Assistant Chief Consultant at the VA Pharmacy Benefits Management Service, and is part of a management team that oversees formulary management, contracting, and emergency pharmacy services for the VA on a national level. Jennifer is actively involved with both the Midwestern University Chicago College of Pharmacy and Rosalind Franklin University College of Pharmacy, having been appointed to adjunct faculty positions.



**Jonathan Lacro, PharmD, BCPP, BCPS**, has been a member of CPNP since 2002. He has served as Research Committee Chair in the past and member of various CPNP committees and task forces. He is a Past Chair of the Board of Pharmacy Specialties Council for Psychiatric Pharmacy. He is currently Director of Pharmacy Education and Training at the VA San Diego Healthcare System (VASDHS) and also serves as the Program Director for their PGY1 Pharmacy Practice and PGY2 Psychiatric Pharmacy Practice Residency programs. Jon's clinical service and research is primarily devoted to schizophrenia and other psychotic disorders, geriatric psychiatry and the optimal use of psychopharmacologic therapies.



**Megan Ehret, PharmD, BCPP**, has been a member of CPNP since 2004. She has served CPNP as a past board member in the role of member at large and is incoming chair of the Review Course editorial board. Megan is currently an associate professor at the University of Connecticut. Her research interests are in evidence-based practice and medication adherence. Her previous research regarding the development of a medication adherence guide to assist in the transition of inmates back into the community won awards from CPNP and NCDEU.

## 2014 RECERTIFICATION PRODUCT REGISTRATION NOW OPEN

2014  
Preparatory and Recertification Programs for the BCPP

Contributor as a Board Certified Psychiatric Pharmacist (BCPP) must complete the following requirements to maintain certification:

- 1. Complete the CPNP Preparatory and Recertification Programs for the BCPP.
- 2. Complete the CPNP Board Certified Psychiatric Pharmacist (BCPP) Examination.
- 3. Complete the CPNP Board Certified Psychiatric Pharmacist (BCPP) Maintenance of Certification (MOC) Program.

For more information, visit [www.cpnp.org](http://www.cpnp.org)

[Registration](#) is now available for CPNP's 2014 recertification products. As the only BPS certified provider of BCPP recertification education, CPNP offers 3 products annually in the ACPE and BCPP Recertification credit increments noted in the table below.

A new edition of the Psychiatric Pharmacotherapy Review Course (formally known as the BCPP Examination Review and Recertification Course) launches January 27. This course continues to offer 20 hours of ACPE and BCPP credit and is required a minimum of once in a recertifier's 7-year cycle. The course is also available as a non-credit purchase for those sitting for the BCPP for the first time and those desiring a quality reference and teaching tool.

The 2014 literature analysis will release March 3 and will feature current articles in the areas of:

- Migraine/headaches
- Suicidal Ideation
- Schizophrenia
- Mood Disorders
- Social Anxiety Disorder

Lastly the Live/Online program will debut at the CPNP Annual Meeting on April 27, 2014 with the following featured topics and speakers:

**Are Atypical Antipsychotics Really Mood Stabilizers?**

**Moderator:** Glen Stimmel, PharmD, BCPP, Professor, USC, Los Angeles, CA

**S. Nassir Ghaemi, MD, MPH,** Professor of Psychiatry and Pharmacology, Director, Mood and Anxiety Disorder Clinic, Tufts Medical Center, Boston, MA

**Gary Sachs, MD,** Associate Professor of Psychiatry, Harvard Medical School, Director, Bipolar Clinic and Research Program, Massachusetts General Hospital, Boston, MA

**Rational or Irrational: Polypharmacy in Psychiatry**

**Rex Lott, PharmD, BCPP,** Professor of Pharmacy Practice, Idaho State University School of Pharmacy, Boise, ID




**Managing Drug Shortages in the Provision of Electroconvulsive Therapy**

**Amy Vandenberg, PharmD, BCPP,** Clinical Assistant Professor, Medical University of South Carolina, MUSC Medical Center & South Carolina College of Pharmacy, Charleston, SC


**Eating Disorders: What's on the Menu for Pharmacologic Treatment?**

**Kimberli McCallum, MD, CEDS, FAPA, CEO, Medical Director, and Founder, McCallum Place Eating Disorders Recovery Centers, St. Louis, MO**

**2014 BCPP Recertification Programming Products**

			
	Psychiatric Pharmacotherapy Review Course*	BCPP Recertification Literature Analysis	BCPP Recertification Live/Online Programming
Contact Hours	<b>20.0 Hours</b>	<b>10.0 Hours</b>	<b>5.0 Hours</b>
Release Date	January 27, 2014	March 3, 2014	April 27, 2014
Examination Deadline	July 23, 2014	August 21, 2014	October 27, 2014

**CASE ON DEVELOPING A FIRST-LINE DEPRESSION PLAN AVAILABLE COMPLIMENTS OF CPNP AND POWERPAK**



A CPNP educational activity, *Down in the Dumps: Developing a Depression Treatment Plan*, is available [online](#). This application-based case is approved for 1 contact hour of ACPE credit and is designed for pharmacists and other healthcare professionals with minimal experience in psychiatry who have an interest in learning more about the treatment of depression. This hands-on activity provides the opportunity to develop an appropriate treatment and monitoring plan for a patient

with depression. Learning is reinforced through an examination with answer justifications and an evidence-based, referenced case key. There is no fee for the activity and participants must complete an exam and evaluation at the end of the activity in order to receive 1.0 contact hour (0.10 CEUs) of continuing pharmacy education credit.

Authored by Jacque Canning, PharmD, BCPP, and edited by Leonard Rappa as primary editor and Sarah Grady, Michael McGuire and Leigh Anne Nelson as secondary editors, this is the first in a series of over 30 cases that will be released by CPNP in 2013 and 2014 on topics ranging from depression to generalized anxiety disorder to schizophrenia. Each disease state will feature 3 levels of cases with level 1 being designed for those with minimal experience in psychiatry, level 2 for those with casual or moderate experience in psychiatry and level 3 for those with expertise in psychiatry. Each activity features a case scenario and a set of assessment questions requiring treatment planning. Reinforcement of learning is aided through answer justifications and an evidence-based, referenced case key.

This case series is designed to:

- Describe the epidemiology, pathophysiology and assessment findings related to various psychiatric and neurologic conditions.
- Identify diagnostic criteria for various psychiatric and neurologic conditions.
- Implement evidence-based pharmacological and/or nonpharmacological treatment strategies tailored to individual patient needs based on pertinent medical, psychosocial, family, cultural and socioeconomic issues.
- Provide monitoring recommendations for patients treated with psychotropic and neurologic medications.
- Be watching for these cases to start releasing in December 2013 and in the meantime, we hope you enjoy and learn from this introductory depression case experience.

### **ADDICTIONS AND SUBSTANCE ABUSE TOPICS FEATURED AT THE 2014 ANNUAL MEETING: A SPOTLIGHT ON GAMBLING ADDICTION**

Addictions are a common co-morbid condition for individuals living with mental illness. The 2014 Annual Meeting provides a number of sessions focused on this

increasingly growing issue psychiatric pharmacists must treat every day.

According to the National Council on Problem Gambling, an estimated 2 million adults in the United States meet the criteria for "pathological gambling," and 4 to 6 million are considered "problem gamblers." It's an addiction found across economic classes, from lower-class Americans playing for their next paycheck to those wealthy enough to gamble away tens of thousands of dollars within a few hours.

In the newly released DSM-5, gambling disorder joins substance-related addictions in a renamed group called "Addiction and Related Disorders." To be diagnosed with a gambling disorder, a certain set of behaviors must be present over a 12-month period—such as needing to bet with increased amounts of money, being preoccupied with gambling, or tending to chase losses. Currently, gamblers need to exhibit 5 of these behaviors to be diagnosed with a gambling disorder. In the DSM-5, the threshold will be lowered to 4.

Timothy Fong M.D., will be joining us at the Annual Meeting on **Tuesday, April 29, 2014** to present a session on Gambling Addiction with focus on:

- Assessing the current understanding of pathological or compulsive gambling
- Reviewing DSM-5 criteria of compulsive gambling
- Discussing epidemiology and pathophysiology behind compulsive gambling
- Reviewing available evidence regarding pharmacologic and non-pharmacologic treatment options for compulsive gambling.

Dr. Fong is an Associate Clinical Professor of Psychiatry at the Semel Institute for Neuroscience and Human Behavior at UCLA. Dr. Fong was the first accredited addiction psychiatry fellow at the UCLA Neuropsychiatric Institute (2002-2004). Currently, he is the co-director of the UCLA Gambling Studies Program. The purpose of this program is to examine the underlying causes and course of problem and pathological gambling and to develop effective, evidence-based treatments. He is also the director of the UCLA Addiction Medicine Clinic, a teaching clinic that specializes in the treatment of all disorders of addiction. Finally, he is also the director of the UCLA Addiction Psychiatry Fellowship, which provides high-level training in addiction psychiatry.

Learn more about this speaker and topic by visiting the following links:

To get a sneak peak at Dr. Fong presenting on the pathophysiology of gambling, check out this [link](#).

Dr. Fong was also featured in a [recent article](#) on gambling addiction in the November 2013 edition of *Scientific American*.

Finally, visit the [UCLA Gambling Program](#) web pages for additional information.

We look forward to hosting you at the Annual Meeting!

### **SAVVY PSYCHOPHARMACOLOGY FEATURE: SSRIS IN PREGNANCY: WHAT SHOULD YOU TELL YOUR DEPRESSED PATIENT?**

Thanks to our partnership with [Current Psychiatry \(CP\)](#) published through Quadrant Healthcom Inc., another CPNP *Savvy Psychopharmacology* article was featured in the November 2013 edition of *Current Psychiatry*. The goal of this section is to present an evidence-based discussion to guide safe, effective prescribing of psychotropic medications. Abbie Leino and Vicki Ellingrod authored this month's article on [SSRIs in Pregnancy: What Should You Tell Your Depressed Patient?](#)

A reminder that a [special subscription price](#) is available to *Current Psychiatry*, a monthly peer-reviewed publication, and the leading source of practical, evidence-based information for healthcare professionals treating psychiatric patients. Thanks to the CPNP partnership with *Current Psychiatry*, CPNP members can receive a year of *Current Psychiatry* at a cost of \$38.

### **DECEMBER 2013 MEMBER NEWS**

Congratulations!

**Beth Hall**, on the birth of her daughter on November 18.

**Kelly Lee, PharmD, BCPP, MAS, FCCP**, has been appointed to the Board of Pharmacy Specialties 2014 Psychiatric Pharmacy Specialty Council as a specialist member.

**Robert Haight, PharmD, BCPP**, co-authored an article that was published in the October issue of *informa healthcare*. [Read the article](#).

**Klugh Kennedy, BS, PharmD, BCPP, FASHP**, and **Eric Kutscher, PharmD, BCPP, FASHP**, co-authored an article in *CNS Drugs*. [Read the article](#).

#### **How to cite this news article:**

CPNP Announcements. *Ment Health Clin* [Internet]. 2013 ;3(6):330-3. Available from: <http://dx.doi.org/10.9740/mhc.n183742>